Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02457598
Title Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Gilead Sciences
Indications

marginal zone B-cell lymphoma

chronic lymphocytic leukemia/small lymphocytic lymphoma

B-cell lymphoma

chronic lymphocytic leukemia

Waldenstroem's macroglobulinemia

mantle cell lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

Entospletinib + Tirabrutinib

Tirabrutinib

Idelalisib + Obinutuzumab + Tirabrutinib

Entospletinib + Obinutuzumab + Tirabrutinib

Idelalisib + Tirabrutinib

Age Groups: adult | senior
Covered Countries USA | FRA


No variant requirements are available.